Lilly’s new twist-WEB ONLY
To survive in an uncertain future, Eli Lilly and Co. needs drugs that develop faster and cheaper and that perform better. Biotech drugs, Lilly executives insist, fit that bill. That’s why Lilly shelled out $6.5 billion to buy the biotech fi rm ImClone Systems Inc. in November, six months after it opened its own $1 […]